ECE2013 Poster Presentations Male reproduction (41 abstracts)
Strength training and testosterone treatment have opposing effects on migration inhibitor factor levels in ageing men
Dorte Glintborg 1 , Louise L Christensen 1 , Thue Kvorning 2 , Rasmus Larsen 3 , Kim Brixen 1 , David M Hougaard 4 , Bjørn Richelsen 5 , Jens M Bruun 5, & Marianne S Andersen 1
1Department of Endocrinology, Odense University Hospital, Odense, Denmark; 2Institute of Sport Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark; 3Department of Informatics and Mathematical Modelling, Technical University of Denmark, Kgs Lyngby, Denmark; 4Department of Clinical Biochemistry and Immunology, Statens Serum Institute, Copenhagen S, Denmark; 5Department of Internal Medicine and Endocrinology (MEA), Aarhus University Hospital, Aarhus, Denmark; 6Medical Department, Regional Hospital Randers, Randers, Denmark.
Objective: The beneficial effects of testosterone treatment (TT) in men with low normal testosterone levels are debated. Chemokine levels have not previously been evaluated during TT in combination with strength training (ST).
Design: A randomized, double-blinded, placebo-controlled study of 6 months TT (gel) in 54 men aged 60–78 years with bioavailable testosterone (BioT) <7.3 nmol/l and waist circumference >94 cm randomized to TT (50–100 mg/day, n=20), placebo (n=18) or ST (n=16) for 24 weeks. Moreover, the ST group was randomized to TT (n=7) or placebo (n=9) after 12 weeks.
Methods: Clinical evaluation and chemokine measurements (migration inhibitor factor (MIF), monocyte chemoattractant protein (MCP)-1, and macrophage inflammatory protein (MIP)-1α). Lean body mass (LBM) and regional fat mass (total, central and extremity) were established by dual x-ray absorptiometry and visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) were measured by magnetic resonance imaging.
Results: Following 24 weeks intervention, MIF and SAT were decreased during ST+placebo vs placebo, whereas BioT and LBM were unchanged.
TT decreased fat mass (total, central, extremity, SAT) and increased BioT and LBM vs placebo. MIF levels increased during TT vs ST+placebo.
ST+TT decreased fat mass (total, central, extremity) and increased BioT and LBM vs placebo.
Following the last 12 weeks of treatment, MCP-1 levels increased during TT vs placebo and MCP-1 levels decreased during ST+placebo vs placebo.
Conclusion: ST+placebo was associated with decreased MIF levels suggesting decreased inflammatory activity. In contrast, TT may be associated with increased inflammatory activity.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more